Serina Therapeutics, Inc.

This biotechnology company develops therapeutic candidates targeting neurological diseases and pain conditions. Its pipeline centers on POZ conjugate technology, a delivery platform designed to improve drug efficacy and tolerability. The lead candidate, SER 252 (POZ-apomorphine), is in preclinical development for advanced Parkinson's disease, while SER 214, a POZ conjugate of rotigotine, has completed Phase 1a trials for early Parkinson's disease and Restless Leg Syndrome. The company is also developing POZ-lipids as a non-immunogenic alternative to conventional PEG-lipids used in lipid nanoparticle formulations.

Beyond its neurological pipeline, the company is exploring applications of its POZ technology platform in lipid nanoparticle-delivered RNA vaccines for infectious diseases. This represents a potential revenue diversification opportunity beyond its primary neurology focus.

The company operates with a lean structure of 12 full-time employees and is headquartered in Huntsville, Alabama. As a publicly listed entity on the NYSE, it operates as a development-stage biotech with limited to no meaningful revenue, typical of companies in early-to mid-stage clinical development.